Jessica Castellanos-Diaz
Endocrinology, Diabetes & Metabolism · Davenport, FLNPI 1295117489
Payments from drug & device makers
Across 80 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$257
- AstraZeneca$228
- Bayer$171
- Novartis$150
- Tandem Diabetes Care, Inc.$141
- Novo Nordisk$135
- plus $779 from 14 others
What the payments were for
- Food & beverage$1,80797%
- Education$533%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 15 | $257 |
| AstraZeneca | 3 | $228 |
| Bayer | 3 | $171 |
| Novartis | 8 | $150 |
| Tandem Diabetes Care, Inc. | 6 | $141 |
| Novo Nordisk | 8 | $135 |
| Sanofi-aventis U.S. LLC | 7 | $131 |
| Lilly USA, LLC | 7 | $128 |
| Johnson & Johnson(2 entities) | 2 | $76 |
| Amgen | 5 | $71 |
| Acella Pharmaceuticals, LLC | 1 | $67 |
| Abbott | 3 | $56 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Merck | 2 | $41 |
| Insulet Corporation | 2 | $40 |
| Lifescan, Inc. | 2 | $36 |
| Boehringer Ingelheim | 1 | $27 |
| Exact Sciences | 1 | $23 |
| Nevro Corp. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,860 in reported general payments places this provider in the 35th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $159,055 |
| JardianceEmpagliflozin | 90 | $122,392 |
| TrulicityDulaglutide | 83 | $99,050 |
| MounjaroTirzepatide | 56 | $84,429 |
| FarxigaDapagliflozin Propanediol | 20 | $22,900 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $21,697 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $16,434 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $9,540 |
| Humalog Kwikpen U-100Insulin Lispro | 38 | $8,342 |
| NovologInsulin Aspart | 11 | $4,222 |
| Novolog FlexpenInsulin Aspart | 14 | $3,044 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 42 | $2,992 |
| Testosterone | 13 | $1,722 |
| Easy Comfort Pen NeedlePen Needle, Diabetic | 11 | $1,036 |
| Glipizide ErGlipizide | 48 | $938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $128 | $183,479139 claims |
| Novo NordiskOzempic, Novolog | $135 | $163,277117 claims |
| Boehringer IngelheimJardiance | $27 | $122,39290 claims |
| AstraZenecaFarxiga | $228 | $22,90020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Davenport
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.